AbstractBackground: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's lymphoma (HL). We studied a high-dose chemotherapy regimen based on thiotepa, etoposide and carboplatin (TECA).Methods: Fifty-eight patients with advanced HL were treated with thiotepa, etoposide and carboplatin for transplant induction.Results: The overall response rate was 79·3% (39 CR: 67·2%; and 7 PR: 12·1%); 12 patients (20·1%) were non-responders. The 5-year overall survival rate was 77·6%; five initially responder patients relapsed within the first 5 years of follow-up and underwent salvage therapy.Conclusion: The TECA conditioning regimen for ASCT in HL results in a good anti-HL effect, positive response to treatment and high...
Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem...
AbstractThe major cause for failure of autologous stem cell transplantation for hematologic malignan...
Autologous stem cell transplantation (ASCT) is commonly used in relapsed or refractory non-Hodgkin's...
Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's...
High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation genera...
Purpose: As well as standard chemotherapy, autologous stem cell transplantation (ASCT) is also seen ...
To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should...
Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Ho...
AbstractThere are limited data to guide the choice of high-dose therapy (HDT) regimen before autolog...
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has be...
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among whic...
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and predniso...
AbstractBusulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen fo...
AbstractOver a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin...
We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemo...
Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem...
AbstractThe major cause for failure of autologous stem cell transplantation for hematologic malignan...
Autologous stem cell transplantation (ASCT) is commonly used in relapsed or refractory non-Hodgkin's...
Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's...
High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation genera...
Purpose: As well as standard chemotherapy, autologous stem cell transplantation (ASCT) is also seen ...
To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should...
Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Ho...
AbstractThere are limited data to guide the choice of high-dose therapy (HDT) regimen before autolog...
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has be...
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among whic...
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and predniso...
AbstractBusulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen fo...
AbstractOver a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin...
We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemo...
Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem...
AbstractThe major cause for failure of autologous stem cell transplantation for hematologic malignan...
Autologous stem cell transplantation (ASCT) is commonly used in relapsed or refractory non-Hodgkin's...